Cost-effectiveness of the use 23-valent pneumococcal polysaccharide vaccine to prevent secondary bacterial infections related to pandemic influenza in Brazil | Zendy

Megan A. O’Brien | Zendy; Praveen Dhankhar | Zendy; John D. Grabenstein | Zendy; Erik J. Dasbach | Zendy

Open Access

Cost-effectiveness of the use 23-valent pneumococcal polysaccharide vaccine to prevent secondary bacterial infections related to pandemic influenza in Brazil

Author(s) -

Megan A. O’Brien,

Praveen Dhankhar,

John D. Grabenstein,

Erik J. Dasbach

Publication year - 2010

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2010.02.617

Subject(s) - vaccination , pandemic , medicine , pneumococcal polysaccharide vaccine , cost effectiveness , influenza vaccine , population , pneumococcal infections , cost effectiveness analysis , vaccine efficacy , immunology , environmental health , disease , pneumococcal disease , covid-19 , streptococcus pneumoniae , infectious disease (medical specialty) , biology , risk analysis (engineering) , bacteria , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research